Prime Time for Superficial Femoral Artery (SFA) - The SFA Study

Not Applicable

Terminated

• Conditions: Peripheral Vascular Disease
• Interventions: Procedure: Cryoplasty (PolarCath peripheral balloon catheter); Procedure: Laser Angioplasty (Spectranetics); Procedure: SilverHawk Atherectomy; Device: Viabahn Endograft; Procedure: Angioplasty/Stent (Guidant "Absolute" stent)

• Registration Number: NCT00902317
• Lead Sponsor: Arizona Heart Institute

Brief Summary

The purpose of this study is to compare the different endovascular treatment modalities for the femoropopliteal segment, and to determine technical success, efficacy and patency at mid-term follow-up. Modalities include; Angioplasty/stent (Control group, Guidant), Cryoplasty/stent (Boston Scientific), Laser Angioplasty/stent (Spectranetics), SilverHawk Atherectomy/stent (Fox Hollow), and Viabahn Endograft (WL Gore).

Detailed Description

Peripheral vascular occlusive disease is a progressive and often debilitating form of atherosclerosis affecting the vessels of the upper and lower extremities. Patients typically present with complaints of pain in the involved extremity (claudication), others present with numbness, heaviness, or fatigue in the affected limb. With regards to the progression of the disease, up to 10% of patients with intermittent claudication may progress to limb loss over the course of 5 years. Past studies indicated that 2/3 of the patients' symptoms remained stable. Most recent studies, however, suggest that the natural history results in more disabling symptoms.

These patients can be evaluated with non-invasive studies including Ankle-Brachial Indices (ABI) or arterial duplex to assess the arterial flow. If stenosis or total occlusion is identified, an invasive study (angiogram) may be necessary. From these studies we are able to determine if the patient is a candidate for either a traditional surgical procedure (bypass) or a percutaneous treatment, similar to the angiogram.

The superficial femoral artery (SFA) has been the region most difficult to treat and maintain patency. Stenosis and/or occlusion often can occur by 6 months. Results of balloon angioplasty and stenting in the femoropopliteal segment have been for the most part variable and often with poor results. The SFA and popliteal arteries are extremely difficult to treat because the diffuse nature of disease, high degree of recoil, amplified reactivity, large number of occlusions, calcification, and the impact of inflow and run-off.

Angioplasty alone, is limited by a high frequency of dissection, significant recoil, and unacceptably high restenosis rates. While stenting has made an acute impact on dissection and recoil, restenosis rates have only modestly improved over time. More aggressive stent utilization has created other problems; in-stent restenosis, occlusion and stent-strut fracture.

Now, percutaneous revascularization has become an option for many patients due to a minimal invasive nature. Various other modalities have been used most recently to treat the femoropopliteal region, including the cool laser, atherectomy, cryoplasty and endoluminal grafts in an attempt to obtain a long-lasting result. At present, few studies compare the use of other devices different from stents in this anatomical location.

Randomization is done before the intervention by opening a sealed envelope containing the type of procedure. All procedures will be done under systemic heparinization using 3 to 5K ui of IV heparin. All cases will be approached percutaneously from the contralateral CFA to prevent that the access site interfere with patency outcome (i.e., antegrade approach). The use of stents as adjunctive Rx in laser, atherectomy, balloon angioplasty and cryoplasty cases will be a sole decision of the interventionist. PTA and stent will be the control group. To maintain uniformity, the stent to be used during the entire series will be the Guidant "Absolute" stent. The laser probe to be used in the study, is the 2.0, 2.2, or 2.5 mm (0.35 compatible) concentric catheter - Spectranetics. The endoluminal graft for the series is the Viabahn - W.L. Gore. The use of closure devices in the access site, will be decision of the interventionist. All patients should be treated post-op with Plavix 75 mg orally for three months starting the day of the intervention.

All subjects will be evaluated pre-procedure, 2 weeks, 3, 6, and 12 months. Subject follow-up at 2 weeks, 3, 6, and 12 months will include Bilateral ABIs, Arterial Duplex, and a Complete Physical Exam/Clinical Symptoms (presence of pulses).

Study Timeline

• Study Start: 2004-11
• Status Verified: 2009-05
• Primary Completion: 2009-05
• Study Completion: 2009-05
• Study First Submitted: 2009-05-14
• Study First Submitted QC: 2009-05-14
• Last Update Submitted: 2009-05-14
• Study First Posted: 2009-05-15
• Last Update Posted: 2009-05-15

Recruitment & Eligibility

• Status: TERMINATED
• Sex: All
• Target Recruitment: 130

Inclusion Criteria

• Stenosis > 70% or total occlusion of the femoropopliteal segment that do not include the origin of the SFA.
• SFA and popliteal of > 4 mm in diameter.
• TASC classification A, B, and C.
• At least one vessel run-off.

Exclusion Criteria

• Age < 18 years old.

• Medical condition that may cause the patient not to be compliant with follow-up (Ex. terminal cancer).

• Pregnancy

• Unwilling or unable to comply with the follow-up.

• Inability or refusal of informed consent.

• Medical Exclusion Criteria:

  • Systemic Infection (sepsis)
  • Bleeding diathesis unable to use anticoagulation.
  • Untreatable reaction to contrast material.

• Anatomical Endovascular Exclusion Criteria:

  • SFA/Popliteal artery < 4 mm diameter.
  • Total occlusion of femoral artery with non-visualization of the origin of the SFA.
  • Previous SFA/popliteal intervention (PTA, stenting etc.)
  • Acute ischemia and/or acute thrombosis of the SFA-Popliteal segment.
  • TASC type D.

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
Boston Scientific	Cryoplasty (PolarCath peripheral balloon catheter)	The PolarCath peripheral balloon catheter (CryoVascular Systems, Inc., Los Gatos, CA) is a novel angioplasty system that simultaneously dilates and cools the plaque and vessel wall in the area of treatment. Cooling is achieved by inflating the balloon with nitrous oxide rather than the usual saline/contrast mixture.
Spectranetics	Laser Angioplasty (Spectranetics)	The excimer laser has unique properties that make it ideally suited to debulk atheromatous and thrombotic arterial blockages. LASER is an acronym for Light Amplification by Stimulated Emission of Radiation. However, there are many types of lasers, each distinguished by the wavelength of the emitted light, the effective power of the light beam, and whether the light is pulsed (like a flashbulb) or continuous (like a light bulb). The effectiveness of a given laser for intraarterial applications depends on how the light interacts with tissue inside an artery.
Fox Hollow	SilverHawk Atherectomy	The SilverHawk peripheral catheter system and cutter driver (FoxHollow Technologies, Redwood City, CA) are designed for the treatment of de novo and restenotic atherosclerotic lesions located in the native peripheral arteries. The catheter consists of a flexible shaft designed to track over a 0.014" guidewire. At the distal end of the catheter is a small cutting assembly comprised of a rotating inner blade contained within a tubular housing. The proximal end of the catheter contains a connector and Positioning Lever designed to fit into a small, disposable, battery-driven Cutter Driver which powers the device.
WL Gore	Viabahn Endograft	Viabahn Endoprosthesis (W.L. Gore \& Associates, Flagstaff, AZ) is a flexible self-expanding endoluminal device consisting of expanded polytetrafluoroethylene (ePTFE) lining with an external Nitinol (NiTi=Nickel:Titanium) support extending along its entire length. The device is compressed and attached to a catheter delivery system. The Gore Viabahn Endoprosthesis is available in a wide range of diameters and lengths.
Control Group, Guidant	Angioplasty/Stent (Guidant "Absolute" stent)	Balloon angioplasty is a treatment that uses a catheter with a tiny balloon mounted on the end. The balloon is positioned through the narrowing/blockage in your leg artery, and then it is inflated to push the narrowing apart and restore a channel for blood flow. The balloon is then deflated and removed from your body. A Stent is a metal scaffold that is also delivered by a catheter and positioned through the narrowing in the artery. The stent is then expanded against the wall of the blood vessel to provide a wider channel for blood flow. The stent remains implanted in the blood vessel, and after a few weeks, the inner lining of the blood vessel will grow over the stent surface. The FDA has approved the use of certain stents for the treatment of narrowing in the leg arteries. Stents have been widely used in various parts of the body, including blocked blood vessels in the arms, legs, heart (coronary arteries), and kidneys (renal arteries).

Primary Outcome Measures

Name	Time	Method
Determine if the devices (laser, atherectomy, polarcath, and viabahn endograft) offer better treatment, better outcome, and better patency than the angioplasty/stent treatment to the femoral artery.	2 weeks, 3, 6, and 12 months

Trial Locations

Locations (1)

Arizona Heart Institute; 🇺🇸 Phoenix, Arizona, United States